Drug research

Lifileucel

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as LN - 144; LN-144; LN-144, TIL, autologous tumor-infiltrating lymphocytes; TIL; Tumor-Infiltrating Lymphocytes

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.NCT06481592	IOVA	Phase 2	Recruiting	2028-05Estimated
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsNCT03645928	IOVA	Phase 2	Terminated	2026-02-20Actual
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic MelanomaNCT02360579	IOVA	Phase 2	Completed	2024-10-24Actual
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced MelanomaNCT07288203	IOVA	Phase 2	Active not recruiting	2032-12Estimated

IOVARecruitingPrimary completion: 2028-05 · Estimated

Trial details

IOVATerminatedPrimary completion: 2026-02-20 · Actual

Trial details

IOVACompletedPrimary completion: 2024-10-24 · Actual

Trial details

IOVAActive not recruitingPrimary completion: 2032-12 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.